China NT Pharma Group Co., Ltd. (HK:1011) has released an update.
China NT Pharma Group Co., Ltd. has announced supplemental information to their 2023 Annual Report, detailing their transition to a light asset operation with a focus on OEM manufacturing, pharmaceuticals and medical devices agency roles, and medical digital services. The Group emphasizes their investment in bone health, including distribution of their own orthopedic drug and international licensing partnerships, and aims to become the leader in China’s orthopedic field. They have also established various platforms for medicine distribution, cross-border health, medical device promotion, and medical digital services, targeting expansion in 2024.
For further insights into HK:1011 stock, check out TipRanks’ Stock Analysis page.
